期刊文献+

西那卡塞及碳酸镧联合骨化三醇治疗慢性肾衰竭透析患者继发重度甲状旁腺功能亢进的疗效观察 被引量:12

Clinical effect of cinacalcet combined with large dose calcitriol and lanthanum carbonate on hemodialysis patients with secondary hyperparathyroidism
下载PDF
导出
摘要 目的:观察钙敏感受体激动剂西那卡塞和磷结合剂碳酸镧联合骨化三醇治疗慢性肾功能衰竭血液透析患者继发重度甲状旁腺功能亢进症的疗效。方法:选取2016-01~12我院进行规律血液透析尿毒症合并重度继发性甲状旁腺功能亢进症的患者20例,随机分成两组:观察组10例和对照组10例。观察组患者给予西那卡塞片,起始剂量25mg/d,每2周复查一次血钙、血磷、iPTH,根据检测结果逐渐将剂量调整至75mg/d。两组患者均于透析后当晚口服骨化三醇,4~6μg,每周二次;所有患者均有不同程度的高磷血症,给予口服碳酸镧500mg,每日3次。将150pg/m L<iPTH<300pg/m L认定为达标。所有患者观察治疗前及治疗后1,2,3,6个月血清钙,磷,iPTH,计算钙磷乘积,进行比较。结果:治疗后观察组血iPTH水平明显低于对照组,差异有统计学意义(P<0.05);两组患者治疗后血磷均较治疗前明显下降,差异有统计学意义(P<0.05);观察组血钙及血钙磷乘积明显低于对照组,差异有统计学意义(P<0.05)。治疗6个月后,对照组显效2例,有效2例,总有效率40%;观察组显效4例,有效3例,总有效率70%;2组总有效率比较差异有统计学意义(P<0.05)。结论:西那卡塞联合骨化三醇冲击及碳酸镧治疗血液透析患者中重度SHPT有较好的疗效,可有效降低iPTH。三种药物联合治疗重度SHPT明显优于单纯骨化三醇冲击加碳酸镧。 Objective:To observe the clinical effect of cinacalcet and lanthanum carbonate combined with large dose calcitriol on hemodialysis patients with severe secondary hyperparathyroidism( SHPT).Methods:20 Hemodialysis patients( 20 cases) with severe SHPT were randomly divided into control and observation groups with10 cases in each.These serum iPTH levels were more than 600 mg/d L.The patients in the observation group were treated with Cinacalcet Hydrochloride Tablets,and the initial dosage was 25 mg/d.The dosage was adjusted according to the patient tolerance,every 2 ~ 4 weeks once,and the maximum dosage was 75 mg/d.The patients in the two groups were all treated with oral large dose of calcitriol 4 ~ 6μg two times per week at night after hemodialysis.The dosage of calcitriol were regulated according to the value of serum iPTH every month.All of the patients were treated with oral 500 mg lanthanum carbonate three times per day.Serum calcium,phosphate and iPTH were measured at baseline and in 6 month after therapy.Results:After treatment,serum iPTH in observation group significantly decreased than in the control group( P < 0.05).Calcium and calcium-phosphorus( Ca × P) in observation group were lower than in the control group( P < 0.05).Conclusion:Cinacalcet combined with large dose of calcitriol and lanthanum carbonate is significantly efficacious in treating severe SHPT.The combination of these three drugs is significantly superior to the combination of calcitriol and lanthanum carbonate in treating severe SHPT.
出处 《黑龙江医药科学》 2018年第1期43-45,共3页 Heilongjiang Medicine and Pharmacy
基金 黑龙江省教育厅基础研究项目 编号:2016-KYYWF-0590
关键词 西那卡塞 碳酸镧 骨化三醇 继发重度甲状旁腺功能亢进 cinacalcet calcitriol lanthanum carbonate secondary yperparathyroidism
  • 相关文献

参考文献3

二级参考文献61

  • 1Ohtsuka N, Urayama K. Pharmacological Action and Clinical Effects of Falecalcitrol, a Highly Potent Derivative of Active Vitamam D3 [ J ] Nippon Yakurigaku Zasshi, 2002, 120 ( 6 ) : 427-436.
  • 2Brown A J, Dusso A S, Slatopolsky E. Vitmam D Analogues for Secondary Hyperparathyroidism[J]. Nephrol Dial Transplant, 2002,17 (S10): 10-19.
  • 3Wada M, Furuya Y, Sakiyama J. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest, 1997,100 : 2977 -2983.
  • 4Antonsen JE, Sherrard D J, Andress DL, et al. A calcimimetic agent acutely suppresses parathyroid hormone levels in patients with chronic renal failure. Rapid communication. Kidney Int, 1998,53:223-227.
  • 5Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol,2010,12:2305-2314.
  • 6Komaba H, Nakanishi S, Fujimori A, et al. Cinaealeet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol,2010,5:2305-2314.
  • 7Block GA, Martin KJ, de Francisco AL, et al. Cinaealcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med, 2004,350 : 1516-1525.
  • 8Messa P, Macario F, Yaqoob M, et al. The OPTIMA study : assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol,2008 ,3 :36-45.
  • 9Fishbane S, Shapiro WB, Corry DB, et al. Cinacalcet HC1 and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol,2008,3 : 1718-1325.
  • 10Strippoli GF,Tong A, Palmer SC, et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev ,2006,18 : CD006254.

共引文献33

同被引文献85

引证文献12

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部